查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2020159

人類胰島素市場規模、佔有率、成長及全球產業分析：按類型、應用和地區分類的洞察，2026-2034 年預測

Human Insulin Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 174 Pages | 商品交期: 請詢問到貨日

價格

人類胰島素市場成長要素

2025年全球人胰島素市場規模為202.2億美元，預計2026年將成長至207.9億美元，2034年將達269.3億美元，預測期內年複合成長率為3.29%。2025年，北美市場佔據主導地位，市場佔有率達45.57%，這主要得益於其較高的糖尿病盛行率、完善的醫療保健基礎設施以及大型製藥企業的強大影響力。

胰島素是一種調節血糖值的重要荷爾蒙。它對於控制糖尿病非常重要，這是一種以高血糖為特徵的慢性疾病。第1型糖尿病是由於胰臟幾乎不產生或完全不產生胰島素而引起的，而第2型糖尿病則是由於身體對胰島素產生抗性而引起的。據估計，全球有超過5.37億人患有糖尿病，預計未來幾年這一數字將顯著成長，這很可能會推高對胰島素治療的需求。

新冠疫情的影響

新冠疫情對人類胰島素市場造成了負面影響，導致2020年市場規模下降5.5%。糖尿病檢測減少、就診次數受限以及醫療資源重心轉向應對新冠疫情，都導致了胰島素需求的下降。然而，隨著醫療服務的重新開放、供應鏈的改善以及新產品的上市，市場在2021年開始復甦。Novo Nordisk和Sanofi等主要企業均報告銷售額回升，反映出市場環境的改善。

市場趨勢

影響市場格局的關鍵趨勢之一是胰島素類似物的日益普及。這些先進配方能更真實模擬天然胰島素的作用機制，進而改善血糖控制，起效更快，並降低低血糖風險。長效胰島素類似物，如Insulin Glargine和Insulin Detemir，因其穩定性和可預測性而越來越受歡迎。

此外，生物相似藥和價格較親民的胰島素產品的推出提高了藥物的可近性，尤其是在新興市場。零售和線上藥局通路的拓展也增加了產品的供應。

市場成長要素

市場成長的主要驅動力是糖尿病盛行率的上升，這歸因於久坐不動的生活方式、肥胖和不健康的飲食習慣。人們對糖尿病的認知不斷提高以及早期診斷的普及也進一步促進了胰島素的使用。

另一個重要因素是創新胰島素產品的上市。製藥公司正大力投資研發，推出包括速效胰島素和長效胰島素在內的新配方。例如，Eli Lilly and Company已推出先進的胰島素療法，以改善血糖控制。口服胰島素給藥系統的持續研究也有望在未來徹底改變糖尿病的治療方式。

抑制因子

儘管有成長機會，但由於許多開發中國家缺乏完善的保險償付體系，市場面臨許多挑戰。高昂的自付費用限制了胰島素治療的普及。此外，糖尿病未確診率高，尤其是在低收入地區，也阻礙了市場擴張。

市場區隔

依類型

由於與傳統胰島素相比，胰島素類似物具有更優異的療效和安全性，因此胰島素類似物在市場上佔據主導地位，預計到2026年將佔市場佔有率的71.63%。

依類型分類的糖尿病

到2026年，第1型糖尿病市場將佔據主導地位，市場佔有率高達62.81%，因為許多患者需要每日注射胰島素才能生存。此外，隨著全球盛行率的不斷上升，第2型糖尿病市場也穩定成長。

依通路

零售藥局和網路藥局佔據市場主導地位，預計到2026年將佔據 92.22%的市場佔有率。這主要歸功於Walmart和Amazon等大型公司的進入，它們提供價格實惠的胰島素產品和便利的購買管道。

區域趨勢

  • 北美：到2025年，北美市場規模達到92.2億美元，呈現強勁成長動能。美國市場預計到2026年將達到86.5億美元。高昂的醫療保健支出和糖尿病的高發生率是推動市場需求的主要因素。
  • 歐洲：在產品創新和強大的醫療保健體系的支持下，到2025年市場規模達到 42億美元，到2026年將達到 43.1億美元。
  • 亞太地區：到2025年達到 42.5億美元，預計到2026年將達到 44.1億美元，主要原因是中國、印度和日本的糖尿病患者人數不斷增加。
  • 拉丁美洲：2025年創造 15.4億美元收入，預計2026年將創造 15.9億美元收入，呈現溫和成長態勢。
  • 中東和非洲：2025年價值 10.2億美元，2026年價值 10.4億美元，但醫療保健資源有限，阻礙了經濟成長。

主要企業及產業趨勢

市場競爭非常激烈，主要參與者包括：

  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Sanofi
  • Biocon

近期發展包括建立合作夥伴關係、推出生物相似藥以及製定目的是提高藥品可及性的定價策略。2023年，Novo Nordisk與Aspen Pharmacare合作，擴大在非洲的胰島素生產。同時，生物相似藥的核准加劇了市場競爭。

目錄

第1章 引言

第2章 執行摘要

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機會
  • 市場趨勢

第4章 主要考慮因素

  • 主要企業管道分析
  • 價格分析：依主要國家/地區分類，2025年
  • 主要國家糖尿病盛行率（2025年）
  • 品牌分析 - 依主要國家/地區分類
  • 主要企業的市場策略
  • 監管情勢概述 - 主要國家和地區
  • 新冠疫情對市場的影響

第5章 全球人類胰島素市場分析、洞察與預測（2021-2034年）

  • 市場分析、洞察與預測：依類型
    • 胰島素類似物
      • 長效型
      • 速效型
      • 預混合
    • 常規人類胰島素
      • 長效型
      • 短效型
      • 速效型
      • 預混合
  • 市場分析、洞察與預測：依糖尿病類型分類
    • 1型糖尿病
    • 2型糖尿病
  • 市場分析、洞察與預測：依通路分類
    • 醫院藥房
    • 實體店和網路藥局
  • 市場分析、洞察與預測：依地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章 北美人胰島素市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章 歐洲人胰島素市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章 亞太地區人類胰島素市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太地區

第9章 拉丁美洲人胰島素市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲

第10章 中東和非洲人胰島素市場分析、洞察與預測（2021-2034年）

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市場佔有率分析（2025年）
  • 公司簡介
    • Novo Nordisk A/S
    • Eli Lilly and Company
    • Sanofi
    • BIOTON SA
    • Gan & Lee Pharmaceuticals Co Ltd.
    • Biocon
    • Tonghua Dongbao Pharmaceutical
    • Julphar
    • Wockhardt
Product Code: FBI100395

Growth Factors of human insulin Market

The global human insulin market was valued at USD 20.22 billion in 2025 and is projected to grow to USD 20.79 billion in 2026, reaching USD 26.93 billion by 2034, exhibiting a CAGR of 3.29% during the forecast period. North America dominated the market in 2025 with a 45.57% share, driven by high diabetes prevalence, strong healthcare infrastructure, and the presence of major pharmaceutical companies.

Insulin is a critical hormone responsible for regulating blood glucose levels. It is essential for managing diabetes, a chronic disease characterized by high blood sugar levels. Type 1 diabetes occurs when the pancreas produces little or no insulin, while Type 2 diabetes arises when the body becomes resistant to insulin. According to global estimates, over 537 million people are living with diabetes, and this number is expected to rise significantly in the coming years, boosting demand for insulin therapies.

Impact of COVID-19

The COVID-19 pandemic negatively impacted the human insulin market, leading to a 5.5% decline in 2020. Reduced diabetes testing, limited hospital visits, and healthcare focus shifting toward COVID-19 management led to decreased insulin demand. However, the market recovered in 2021 due to resumed healthcare services, improved supply chains, and new product launches. Major companies such as Novo Nordisk A/S and Sanofi reported revenue recovery, reflecting improved market conditions.

Market Trends

A key trend shaping the market is the growing adoption of insulin analogues. These advanced formulations mimic natural insulin more closely and offer better glycemic control, faster action, and reduced risk of hypoglycemia. Long-acting insulin analogues such as insulin glargine and insulin detemir are increasingly preferred due to their stability and predictability.

Additionally, the introduction of biosimilar and affordable insulin products is improving accessibility, particularly in emerging markets. The expansion of retail and online pharmacy channels is also enhancing product availability.

Market Growth Drivers

The primary driver of market growth is the rising prevalence of diabetes, fueled by sedentary lifestyles, obesity, and unhealthy dietary habits. Increasing awareness and early diagnosis are further boosting insulin adoption.

Another important factor is the launch of innovative insulin products. Pharmaceutical companies are investing heavily in research and development to introduce new formulations, including rapid-acting and long-acting insulin. For instance, Eli Lilly and Company introduced advanced insulin therapies to improve glycemic control. Ongoing research into oral insulin delivery systems is also expected to revolutionize diabetes treatment in the future.

Restraining Factors

Despite growth opportunities, the market faces challenges due to the lack of reimbursement policies in many developing countries. High out-of-pocket expenses limit access to insulin therapy. Additionally, a high rate of undiagnosed diabetes cases, particularly in low-income regions, restricts market expansion.

Market Segmentation

By Type:

The analogue insulin segment dominates, accounting for 71.63% share in 2026, due to its superior efficacy and safety profile compared to traditional insulin.

By Diabetes Type:

The Type 1 diabetes segment leads with 62.81% share in 2026, as patients require daily insulin administration for survival. Type 2 diabetes is also growing steadily due to increasing global prevalence.

By Distribution Channel:

Retail and online pharmacies dominate, contributing 92.22% share in 2026, driven by the entry of major players such as Walmart and Amazon offering affordable insulin products and convenient access.

Regional Insights

  • North America: Valued at USD 9.22 billion in 2025 and projected strong growth, with the U.S. market reaching USD 8.65 billion in 2026. High healthcare spending and diabetes prevalence drive demand.
  • Europe: Recorded USD 4.2 billion in 2025 and USD 4.31 billion in 2026, supported by product innovation and strong healthcare systems.
  • Asia Pacific: Accounted for USD 4.25 billion in 2025 and USD 4.41 billion in 2026, driven by rising diabetes cases in China, India, and Japan.
  • Latin America: Generated USD 1.54 billion in 2025 and USD 1.59 billion in 2026, showing moderate growth.
  • Middle East & Africa: Valued at USD 1.02 billion in 2025 and USD 1.04 billion in 2026, with growth constrained by limited healthcare access.

Key Companies and Industry Developments

The market is highly competitive, with leading players including:

  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Sanofi
  • Biocon

Recent developments include partnerships, biosimilar launches, and pricing strategies to improve accessibility. In 2023, Novo Nordisk partnered with Aspen Pharmacare to expand insulin production in Africa, while biosimilar approvals continue to enhance market competition.

Conclusion

The global human insulin market is expected to grow steadily from USD 20.22 billion in 2025 to USD 26.93 billion by 2034, driven by the increasing prevalence of diabetes and continuous advancements in insulin therapies. While challenges such as limited reimbursement and undiagnosed cases persist, expanding access to affordable insulin and innovation in drug delivery systems will support long-term growth. North America will remain dominant, while emerging regions present significant growth opportunities as healthcare access improves worldwide.

Segmentation By Type

  • Analogue Insulin
    • Long-acting
    • Fast-acting
    • Premix
  • Traditional Human Insulin
    • Long-acting
    • Short-acting
    • Fast-acting
    • Premix

By Diabetes Type

  • Diabetes Type 1
  • Diabetes Type 2

By Distribution Channel

  • Hospital Pharmacies
  • Retail & Online Pharmacies

By Geography

  • North America (By Type, By Diabetes Type, By Distribution Channel, and By Country)
    • U.S. (By Diabetes Type)
    • Canada (By Diabetes Type)
  • Europe (By Type, By Diabetes Type, By Distribution Channel, and By Country)
    • U.K. (By Diabetes Type)
    • Germany (By Diabetes Type)
    • France (By Diabetes Type)
    • Italy (By Diabetes Type)
    • Spain (By Diabetes Type)
    • Scandinavia (By Diabetes Type)
    • Rest of Europe (By Diabetes Type)
  • Asia Pacific (By Type, By Diabetes Type, By Distribution Channel, and By Country)
    • China (By Diabetes Type)
    • Japan (By Diabetes Type)
    • India (By Diabetes Type)
    • Australia (By Diabetes Type)
    • Southeast Asia (By Diabetes Type)
    • Rest of Asia Pacific (By Diabetes Type)
  • Latin America (By Type, By Diabetes Type, By Distribution Channel, and By Country)
    • Brazil (By Diabetes Type)
    • Mexico (By Diabetes Type)
    • Rest of Latin America (By Diabetes Type)
  • Middle East & Africa (By Type, By Diabetes Type, By Distribution Channel, and By Country)
    • GCC (By Diabetes Type)
    • South Africa (By Diabetes Type)
  • Rest of Middle East & Africa (By Diabetes Type)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Pipeline Analysis, By Key Players
  • 4.2. Pricing Analysis, By Key Countries, 2025
  • 4.3. Prevalence of Diabetes, By Key Countries, 2025
  • 4.4. Brand Analysis - By Key Countries
  • 4.5. Key Market Strategies, By Key Players
  • 4.6. Overview of Regulatory Scenario - For Key Countries/Regions
  • 4.7. Impact of COVID-19 on the Market

5. Global Human Insulin Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Analogue Insulin
      • 5.1.1.1. Long-acting
      • 5.1.1.2. Fast-acting
      • 5.1.1.3. Premix
    • 5.1.2. Traditional Human Insulin
      • 5.1.2.1. Long-acting
      • 5.1.2.2. Short-acting
      • 5.1.2.3. Fast-acting
      • 5.1.2.4. Premix
  • 5.2. Market Analysis, Insights and Forecast - By Diabetes Type
    • 5.2.1. Diabetes Type 1
    • 5.2.2. Diabetes Type 2
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacies
    • 5.3.2. Retail & Online Pharmacies
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East and Africa

6. North America Human Insulin Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Analogue Insulin
      • 6.1.1.1. Long-acting
      • 6.1.1.2. Fast-acting
      • 6.1.1.3. Premix
    • 6.1.2. Traditional Human Insulin
      • 6.1.2.1. Long-acting
      • 6.1.2.2. Short-acting
      • 6.1.2.3. Fast-acting
      • 6.1.2.4. Premix
  • 6.2. Market Analysis, Insights and Forecast - By Diabetes Type
    • 6.2.1. Diabetes Type 1
    • 6.2.2. Diabetes Type 2
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Retail & Online Pharmacies
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
      • 6.4.1.1. By Diabetes Type
    • 6.4.2. Canada
      • 6.4.2.1. By Diabetes Type

7. Europe Human Insulin Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Analogue Insulin
      • 7.1.1.1. Long-acting
      • 7.1.1.2. Fast-acting
      • 7.1.1.3. Premix
    • 7.1.2. Traditional Human Insulin
      • 7.1.2.1. Long-acting
      • 7.1.2.2. Short-acting
      • 7.1.2.3. Fast-acting
      • 7.1.2.4. Premix
  • 7.2. Market Analysis, Insights and Forecast - By Diabetes Type
    • 7.2.1. Diabetes Type 1
    • 7.2.2. Diabetes Type 2
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Retail & Online Pharmacies
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
      • 7.4.1.1. By Diabetes Type
    • 7.4.2. Germany
      • 7.4.2.1. By Diabetes Type
    • 7.4.3. France
      • 7.4.3.1. By Diabetes Type
    • 7.4.4. Italy
      • 7.4.4.1. By Diabetes Type
    • 7.4.5. Spain
      • 7.4.5.1. By Diabetes Type
    • 7.4.6. Scandinavia
      • 7.4.6.1. By Diabetes Type
    • 7.4.7. Rest of Europe
      • 7.4.7.1. By Diabetes Type

8. Asia Pacific Human Insulin Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Analogue Insulin
      • 8.1.1.1. Long-acting
      • 8.1.1.2. Fast-acting
      • 8.1.1.3. Premix
    • 8.1.2. Traditional Human Insulin
      • 8.1.2.1. Long-acting
      • 8.1.2.2. Short-acting
      • 8.1.2.3. Fast-acting
      • 8.1.2.4. Premix
  • 8.2. Market Analysis, Insights and Forecast - By Diabetes Type
    • 8.2.1. Diabetes Type 1
    • 8.2.2. Diabetes Type 2
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail & Online Pharmacies
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. China
      • 8.4.1.1. By Diabetes Type
    • 8.4.2. Japan
      • 8.4.2.1. By Diabetes Type
    • 8.4.3. India
      • 8.4.3.1. By Diabetes Type
    • 8.4.4. Australia
      • 8.4.4.1. By Diabetes Type
    • 8.4.5. Southeast Asia
      • 8.4.5.1. By Diabetes Type
    • 8.4.6. Rest of Asia Pacific
      • 8.4.6.1. By Diabetes Type

9. Latin America Human Insulin Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Analogue Insulin
      • 9.1.1.1. Long-acting
      • 9.1.1.2. Fast-acting
      • 9.1.1.3. Premix
    • 9.1.2. Traditional Human Insulin
      • 9.1.2.1. Long-acting
      • 9.1.2.2. Short-acting
      • 9.1.2.3. Fast-acting
      • 9.1.2.4. Premix
  • 9.2. Market Analysis, Insights and Forecast - By Diabetes Type
    • 9.2.1. Diabetes Type 1
    • 9.2.2. Diabetes Type 2
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail & Online Pharmacies
  • 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.4.1. Brazil
      • 9.4.1.1. By Diabetes Type
    • 9.4.2. Mexico
      • 9.4.2.1. By Diabetes Type
    • 9.4.3. Rest of Latin America
      • 9.4.3.1. By Diabetes Type

10. Middle East & Africa Human Insulin Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Analogue Insulin
      • 10.1.1.1. Long-acting
      • 10.1.1.2. Fast-acting
      • 10.1.1.3. Premix
    • 10.1.2. Traditional Human Insulin
      • 10.1.2.1. Long-acting
      • 10.1.2.2. Short-acting
      • 10.1.2.3. Fast-acting
      • 10.1.2.4. Premix
  • 10.2. Market Analysis, Insights and Forecast - By Diabetes Type
    • 10.2.1. Diabetes Type 1
    • 10.2.2. Diabetes Type 2
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Retail & Online Pharmacies
  • 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.4.1. GCC
      • 10.4.1.1. By Diabetes Type
    • 10.4.2. South Africa
      • 10.4.2.1. By Diabetes Type
    • 10.4.3. Rest of Middle East & Africa
      • 10.4.3.1. By Diabetes Type

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Novo Nordisk A/S
      • 11.2.1.1. Overview
      • 11.2.1.2. Product
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. financials (Based on Availability)
    • 11.2.2. Eli Lilly and Company
      • 11.2.2.1. Overview
      • 11.2.2.2. Product
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. financials (Based on Availability)
    • 11.2.3. Sanofi
      • 11.2.3.1. Overview
      • 11.2.3.2. Product
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. financials (Based on Availability)
    • 11.2.4. BIOTON S.A.
      • 11.2.4.1. Overview
      • 11.2.4.2. Product
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. financials (Based on Availability)
    • 11.2.5. Gan & Lee Pharmaceuticals Co Ltd.
      • 11.2.5.1. Overview
      • 11.2.5.2. Product
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. financials (Based on Availability)
    • 11.2.6. Biocon
      • 11.2.6.1. Overview
      • 11.2.6.2. Product
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. financials (Based on Availability)
    • 11.2.7. Tonghua Dongbao Pharmaceutical
      • 11.2.7.1. Overview
      • 11.2.7.2. Product
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. financials (Based on Availability)
    • 11.2.8. Julphar
      • 11.2.8.1. Overview
      • 11.2.8.2. Product
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. financials (Based on Availability)
    • 11.2.9. Wockhardt
      • 11.2.9.1. Overview
      • 11.2.9.2. Product
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. financials (Based on Availability)

List of Tables

  • Table 1: Global Human Insulin Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 2: Global Human Insulin Market Revenue (USD billion) Forecast, by Analogue Insulin, 2021-2034
  • Table 3: Global Human Insulin Market Revenue (USD billion) Forecast, by Traditional Human Insulin, 2021-2034
  • Table 4: Global Human Insulin Market Revenue (USD billion) Forecast, by Diabetes Type, 2021-2034
  • Table 5: Global Human Insulin Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 6: Global Human Insulin Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 7: North America Human Insulin Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 8: North America Human Insulin Market Revenue (USD billion) Forecast, by Analogue Insulin, 2021-2034
  • Table 9: North America Human Insulin Market Revenue (USD billion) Forecast, by Traditional Human Insulin, 2021-2034
  • Table 10: North America Human Insulin Market Revenue (USD billion) Forecast, by Diabetes Type, 2021-2034
  • Table 11: North America Human Insulin Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: North America Human Insulin Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 13: U.S. Human Insulin Market Revenue (USD billion) Forecast, By Diabetes Type, 2021-2034
  • Table 14: Canada Human Insulin Market Revenue (USD billion) Forecast, By Diabetes Type, 2021-2034
  • Table 15: Europe Human Insulin Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 16: Europe Human Insulin Market Revenue (USD billion) Forecast, by Analogue Insulin, 2021-2034
  • Table 17: Europe Human Insulin Market Revenue (USD billion) Forecast, by Traditional Human Insulin, 2021-2034
  • Table 18: Europe Human Insulin Market Revenue (USD billion) Forecast, by Diabetes Type, 2021-2034
  • Table 19: Europe Human Insulin Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Europe Human Insulin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: U.K. Human Insulin Market Revenue (USD billion) Forecast, By Diabetes Type, 2021-2034
  • Table 22: Germany Human Insulin Market Revenue (USD billion) Forecast, By Diabetes Type, 2021-2034
  • Table 23: France Human Insulin Market Revenue (USD billion) Forecast, By Diabetes Type, 2021-2034
  • Table 24: Italy Human Insulin Market Revenue (USD billion) Forecast, By Diabetes Type, 2021-2034
  • Table 25: Spain Human Insulin Market Revenue (USD billion) Forecast, By Diabetes Type, 2021-2034
  • Table 26: Scandinavia Human Insulin Market Revenue (USD billion) Forecast, By Diabetes Type, 2021-2034
  • Table 27: Rest of Europe Human Insulin Market Revenue (USD billion) Forecast, By Diabetes Type, 2021-2034
  • Table 28: Asia Pacific Human Insulin Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 29: Asia Pacific Human Insulin Market Revenue (USD billion) Forecast, by Analogue Insulin, 2021-2034
  • Table 30: Asia Pacific Human Insulin Market Revenue (USD billion) Forecast, by Traditional Human Insulin, 2021-2034
  • Table 31: Asia Pacific Human Insulin Market Revenue (USD billion) Forecast, by Diabetes Type, 2021-2034
  • Table 32: Asia Pacific Human Insulin Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 33: Asia Pacific Human Insulin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 34: China Human Insulin Market Revenue (USD billion) Forecast, By Diabetes Type, 2021-2034
  • Table 35: Japan Human Insulin Market Revenue (USD billion) Forecast, By Diabetes Type, 2021-2034
  • Table 36: India Human Insulin Market Revenue (USD billion) Forecast, By Diabetes Type, 2021-2034
  • Table 37: Australia Human Insulin Market Revenue (USD billion) Forecast, By Diabetes Type, 2021-2031
  • Table 38: Southeast Asia Human Insulin Market Revenue (USD billion) Forecast, By Diabetes Type, 2021-2031
  • Table 39: Rest of Asia Pacific Human Insulin Market Revenue (USD billion) Forecast, By Diabetes Type, 2021-2031
  • Table 40: Latin America Human Insulin Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 41: Latin America Human Insulin Market Revenue (USD billion) Forecast, by Analogue Insulin, 2021-2034
  • Table 42: Latin America Human Insulin Market Revenue (USD billion) Forecast, by Traditional Human Insulin, 2021-2034
  • Table 43: Latin America Human Insulin Market Revenue (USD billion) Forecast, by Diabetes Type, 2021-2034
  • Table 44: Latin America Human Insulin Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 45: Latin America Human Insulin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 46: Brazil Human Insulin Market Revenue (USD billion) Forecast, By Diabetes Type, 2021-2034
  • Table 47: Mexico Human Insulin Market Revenue (USD billion) Forecast, By Diabetes Type, 2021-2034
  • Table 48: Rest of Latin America Human Insulin Market Revenue (USD billion) Forecast, By Diabetes Type, 2021-2034
  • Table 49: Middle East & Africa Human Insulin Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 50: Middle East & Africa Human Insulin Market Revenue (USD billion) Forecast, by Analogue Insulin, 2021-2034
  • Table 51: Middle East & Africa Human Insulin Market Revenue (USD billion) Forecast, by Traditional Human Insulin, 2021-2034
  • Table 52: Middle East & Africa Human Insulin Market Revenue (USD billion) Forecast, by Diabetes Type, 2021-2034
  • Table 53: Middle East & Africa Human Insulin Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 54: Middle East & Africa Human Insulin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 55: GCC Human Insulin Market Revenue (USD billion) Forecast, By Diabetes Type, 2021-2034
  • Table 56: South Africa Human Insulin Market Revenue (USD billion) Forecast, By Diabetes Type, 2021-2034
  • Table 57: Rest of Middle East & Africa Human Insulin Market Revenue (USD billion) Forecast, By Diabetes Type, 2021-2034

List of Figures

  • Figure 1: Global Human Insulin Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Human Insulin Market Value Share (%), by Type, 2025 & 2034
  • Figure 3: Global Human Insulin Market Value Share (%), by Diabetes Type, 2025 & 2034
  • Figure 4: Global Human Insulin Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 5: Global Human Insulin Market Value (USD billion), by Region, 2025 & 2034
  • Figure 6: North America Human Insulin Market Value (USD billion), by Type, 2025 & 2034
  • Figure 7: North America Human Insulin Market Value Share (%), by Type, 2025
  • Figure 8: North America Human Insulin Market Value (USD billion), by Diabetes Type, 2025 & 2034
  • Figure 9: North America Human Insulin Market Value Share (%), by Diabetes Type, 2025
  • Figure 10: North America Human Insulin Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 11: North America Human Insulin Market Value Share (%), by Distribution Channel, 2025
  • Figure 12: North America Human Insulin Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Human Insulin Market Value Share (%), By Country, 2025
  • Figure 14: Europe Human Insulin Market Value (USD billion), by Type, 2025 & 2034
  • Figure 15: Europe Human Insulin Market Value Share (%), by Type, 2025
  • Figure 16: Europe Human Insulin Market Value (USD billion), by Diabetes Type, 2025 & 2034
  • Figure 17: Europe Human Insulin Market Value Share (%), by Diabetes Type, 2025
  • Figure 18: Europe Human Insulin Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 19: Europe Human Insulin Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Europe Human Insulin Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Human Insulin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Human Insulin Market Value (USD billion), by Type, 2025 & 2034
  • Figure 23: Asia Pacific Human Insulin Market Value Share (%), by Type, 2025
  • Figure 24: Asia Pacific Human Insulin Market Value (USD billion), by Diabetes Type, 2025 & 2034
  • Figure 25: Asia Pacific Human Insulin Market Value Share (%), by Diabetes Type, 2025
  • Figure 26: Asia Pacific Human Insulin Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 27: Asia Pacific Human Insulin Market Value Share (%), by Distribution Channel, 2025
  • Figure 28: Asia Pacific Human Insulin Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Human Insulin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Latin America Human Insulin Market Value (USD billion), by Type, 2025 & 2034
  • Figure 31: Latin America Human Insulin Market Value Share (%), by Type, 2025
  • Figure 32: Latin America Human Insulin Market Value (USD billion), by Diabetes Type, 2025 & 2034
  • Figure 33: Latin America Human Insulin Market Value Share (%), by Diabetes Type, 2025
  • Figure 34: Latin America Human Insulin Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 35: Latin America Human Insulin Market Value Share (%), by Distribution Channel, 2025
  • Figure 36: Latin America Human Insulin Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Human Insulin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Human Insulin Market Value (USD billion), by Type, 2025 & 2034
  • Figure 39: Middle East & Africa Human Insulin Market Value Share (%), by Type, 2025
  • Figure 40: Middle East & Africa Human Insulin Market Value (USD billion), by Diabetes Type, 2025 & 2034
  • Figure 41: Middle East & Africa Human Insulin Market Value Share (%), by Diabetes Type, 2025
  • Figure 42: Middle East & Africa Human Insulin Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 43: Middle East & Africa Human Insulin Market Value Share (%), by Distribution Channel, 2025
  • Figure 44: Middle East & Africa Human Insulin Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Human Insulin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 46: Global Human Insulin Market Share (%), By Company, 2025